Bacterial Cellulose—Adaptation of a Nature-Identical Material to the Needs of Advanced Chronic Wound Care
Rattachement africain : de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Modern wound treatment calls for hydroactive dressings. Among the variety of materials that have entered the field of wound care in recent years, the carbohydrate polymer bacterial cellulose (BC) represents one of the most promising candidates as the biomaterial features a high moisture-loading and donation capacity, mechanical stability, moldability, and breathability. Although BC has already gained increasing relevance in the treatment of burn wounds, its potential and clinical performance for “chronic wound” indications have not yet been sufficiently investigated. This article focuses on experimental and clinical data regarding the application of BC within the indications of chronic, non-healing wounds, especially venous and diabetic ulcers. A recent clinical observation study in a chronic wound setting clearly demonstrated its wound-cleansing properties and ability to induce healing in stalling wounds. Furthermore, the material parameters of BC dressings obtained through the static cultivation of Komagataeibacter xylinus were investigated for the first time in standardized tests and compared to various advanced wound-care products. Surprisingly, a free swell absorptive capacity of a BC dressing variant containing 97% moisture was found, which was higher than that of alginate or even hydrofiber dressings. We hypothesize that the fine-structured, open porous network and the resulting capillary forces are among the main reasons for this unexpected result.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Bacterial Cellulose—Adaptation of a Nature-Identical Material to the Needs of Advanced Chronic Wound Care
- Date Crossref
- 30/05/2022
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Evonik (Germany) pays non établi dans la noticeEntreprise
-
Friedrich Schiller University Jena Department of Pharmaceutical/Medicinal Chemistry pays non établi dans la noticeUniversité ou école supérieure
-
Medico-Academic Consultings (Germany) pays non établi dans la noticeEntreprise
-
JeNaCell GmbH—An Evonik Company pays non établi dans la noticeEntreprise
-
Akademie-ZWM AG pays non établi dans la noticeInstitution
-
MCS Medical Consulting pays non établi dans la noticeInstitution
-
Evonik Operations GmbH pays non établi dans la noticeEntreprise
Evonik (Germany), Department of Pharmaceutical/Medicinal Chemistry — Friedrich Schiller University Jena et Medico-Academic Consultings (Germany), avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.